Private Company
Public Company
Subsidiary of
Orthogonal Thinker
Clinical Trials, R&D
Consumer Packaged Goods


Our ambition is to deliver governmental approved therapeutic treatment options that address the current global mental healthcare pandemic.

We seek to provide a free resource to the individual that will provide critical data for further academic understanding of psychoactive compounds.

As the pace of decriminalization continues to snowball, we watch with interest as the legal backdrop and DEA scheduling status remains on the political agenda. In markets that allow self therapy, we anticipate being able to provide a suite of products.